Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Mar 28:19:829-839.
doi: 10.2147/COPD.S452191. eCollection 2024.

Comparison of the Application of Vibrating Mesh Nebulizer and Jet Nebulizer in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis

Zhouzhou Feng  1 , Zhengcai Han  1 , Yaqin Wang  1 , Hong Guo  1 , Jian Liu  1   2
Affiliations
Meta-Analysis

Comparison of the Application of Vibrating Mesh Nebulizer and Jet Nebulizer in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis

Zhouzhou Feng et al. Int J Chron Obstruct Pulmon Dis. .

Abstract

Objective: To comparison of the application of Vibrating Mesh Nebulizer and Jet Nebulizer in chronic obstructive pulmonary disease (COPD).

Research methods: This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statements. The primary outcome measures analyzed included: The amount of inhaler in the urine sample at 30 minutes after inhalation therapy (USAL0.5), The total amount of inhaler in urine sample within 24 hours (USAL24), Aerosol emitted, Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC).

Results: Ten studies were included with a total of 314 study participants, including 157 subjects in the VMN group and 157 subjects in the JN group. The data analysis results of USAL0.5, MD (1.88 [95% CI, 0.95 to 2.81], P = 0.000), showed a statistically significant difference. USAL24, MD (1.61 [95% CI, 1.14 to 2.09], P = 0.000), showed a statistically significant difference. The results of aerosol emitted showed a statistically significant difference in MD (3.44 [95% CI, 2.84 to 4.04], P = 0.000). The results of FEV1 showed MD (0.05 [95% CI, -0.24 to 0.35], P=0.716), the results were not statistically significant. The results of FVC showed MD (0.11 [95% CI, -0.18 to 0.41], P=0.459), the results were not statistically significant. It suggests that VMN is better than JN and provides higher aerosols, but there is no difference in improving lung function between them.

Conclusion: VMN is significantly better than JN in terms of drug delivery and utilization in the treatment of patients with COPD. However, in the future use of nebulizers, it is important to select a matching nebulizer based on a combination of factors such as mechanism of action of the nebulizer, disease type and comorbidities, ventilation strategies and modes, drug formulations, as well as cost-effectiveness, in order to achieve the ideal treatment of COPD.

Keywords: aerosol; chronic obstructive pulmonary disease; jet nebulizers; meta-analysis; vibrating mesh nebulizers.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
PRISMA (preferred reporting items for systematic reviews and meta-analysis) flow diagram. Adapted from Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:160. Creative Commons.
Figure 2
Figure 2
Risk of bias across studies.
Figure 3
Figure 3
Forest plot of USAL0.5.
Figure 4
Figure 4
Forest plot of USAL0.5 after excluding Hassan’s study.
Figure 5
Figure 5
Forest plot of USAL24.
Figure 6
Figure 6
Forest plot of aerosol emitted.
Figure 7
Figure 7
Forest plot of FEV1.
Figure 8
Figure 8
Forest plot of FVC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Agustí A, Celli BR, Criner GJ, et al. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Eur Respir J. 2023;61(4):2300239. doi:10.1183/13993003.00239-2023 - DOI - PMC - PubMed
    1. Wedzicha JA, Ers C-C, Miravitlles M, et al. Management of COPD exacerbations: a European respiratory society/American thoracic society guideline. Eur Respir J. 2017;49(3):1600791. doi:10.1183/13993003.00791-2016 - DOI - PubMed
    1. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3 - DOI - PMC - PubMed
    1. Lexmond A, Forbes B. Drug delivery devices for inhaled medicines. Handb Exp Pharmacol. 2017;237:265–280. doi:10.1007/164_2016_67 - DOI - PubMed
    1. Sorino C, Negri S, Spanevello A, Visca D, Scichilone N. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15–18. doi:10.1016/j.ejim.2020.02.023 - DOI - PubMed

Publication types

MeSH terms